Research programme: C1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development

Drug Profile

Research programme: C1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development

Alternative Names: C1 inhibitors research programme - 3-Dimensional Pharmaceuticals; Complement C1 esterase inhibitors research programme - 3-Dimensional Pharmaceuticals

Latest Information Update: 14 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Lupus vulgaris; Psoriasis; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 14 Jul 2006 No development reported - Preclinical for Lupus in USA (IV)
  • 14 Jul 2006 No development reported - Preclinical for Psoriasis in USA (IV)
  • 14 Jul 2006 No development reported - Preclinical for Reperfusion injury in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top